Targeted chemotherapy overcomes drug resistance in melanoma.
DNA damage response
MAP kinase signaling
cellular dormancy
drug resistance
protein phosphatase 2A
small molecule inhibitor
Journal
Genes & development
ISSN: 1549-5477
Titre abrégé: Genes Dev
Pays: United States
ID NLM: 8711660
Informations de publication
Date de publication:
01 05 2020
01 05 2020
Historique:
received:
18
10
2019
accepted:
13
03
2020
pubmed:
4
4
2020
medline:
31
10
2020
entrez:
4
4
2020
Statut:
ppublish
Résumé
The emergence of drug resistance is a major obstacle for the success of targeted therapy in melanoma. Additionally, conventional chemotherapy has not been effective as drug-resistant cells escape lethal DNA damage effects by inducing growth arrest commonly referred to as cellular dormancy. We present a therapeutic strategy termed "targeted chemotherapy" by depleting protein phosphatase 2A (PP2A) or its inhibition using a small molecule inhibitor (1,10-phenanthroline-5,6-dione [phendione]) in drug-resistant melanoma. Targeted chemotherapy induces the DNA damage response without causing DNA breaks or allowing cellular dormancy. Phendione treatment reduces tumor growth of BRAF
Identifiants
pubmed: 32241802
pii: gad.333864.119
doi: 10.1101/gad.333864.119
pmc: PMC7197350
doi:
Substances chimiques
Antineoplastic Agents
0
Pyrazoles
0
Protein Phosphatase 2
EC 3.1.3.16
phenidone
H0U5612P6K
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
637-649Subventions
Organisme : NCI NIH HHS
ID : DP1 CA228041
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA240139
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM078455
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM105754
Pays : United States
Informations de copyright
© 2020 Yue et al.; Published by Cold Spring Harbor Laboratory Press.
Références
Ann Transl Med. 2016 Jun;4(12):237
pubmed: 27429963
Leuk Lymphoma. 2018 Oct;59(10):2273-2286
pubmed: 29164965
J Med Chem. 2001 May 24;44(11):1777-93
pubmed: 11356112
Pigment Cell Melanoma Res. 2011 Aug;24(4):666-72
pubmed: 21615881
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
Genes Dev. 2017 Sep 1;31(17):1809-1820
pubmed: 28982763
Cell. 2015 Jun 18;161(7):1681-96
pubmed: 26091043
Nat Commun. 2015 Apr 09;6:6683
pubmed: 25865119
Nat Commun. 2017 Oct 23;8(1):1090
pubmed: 29061961
J Chem Inf Model. 2015 Nov 23;55(11):2324-37
pubmed: 26479676
Nature. 2017 Jun 15;546(7658):431-435
pubmed: 28607484
Nat Rev Clin Oncol. 2016 Apr;13(4):209-27
pubmed: 26718105
FASEB J. 2008 Apr;22(4):954-65
pubmed: 18039929
Cancer. 2012 Aug 15;118(16):4014-23
pubmed: 22180178
Biochim Biophys Acta. 2007 Aug;1773(8):1263-84
pubmed: 17126425
Cell Commun Signal. 2010 Sep 22;8:27
pubmed: 20860841
Chem Biol Interact. 2006 Dec 1;164(1-2):115-25
pubmed: 17030029
Nat Rev Cancer. 2003 Jun;3(6):459-65
pubmed: 12778136
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W522-5
pubmed: 17488841
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
Cancer Res. 2014 Nov 1;74(21):5937-41
pubmed: 25320006
BMC Bioinformatics. 2009 Jun 02;10:168
pubmed: 19486540
Proc Natl Acad Sci U S A. 2009 Jul 14;106(28):11697-702
pubmed: 19564615
Cell. 2018 Aug 23;174(5):1216-1228.e19
pubmed: 30057111
J Inorg Biochem. 2014 Dec;141:103-113
pubmed: 25238635
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Nature. 2017 Oct 12;550(7675):270-274
pubmed: 28976960
Nature. 2004 Nov 18;432(7015):294-7
pubmed: 15549090
Biochem Pharmacol. 2004 Sep 15;68(6):1041-7
pubmed: 15313399
Biol Cell. 2001 Sep;93(1-2):53-62
pubmed: 11730323
Nat Cell Biol. 2002 Aug;4(8):556-64
pubmed: 12134156
Cell Discov. 2016 Sep 06;2:16028
pubmed: 27648299
Nature. 2007 Jan 4;445(7123):53-7
pubmed: 17086192
Lancet. 2012 Jul 28;380(9839):358-65
pubmed: 22735384
Nucleic Acids Res. 2015 Jul 1;43(W1):W443-7
pubmed: 25873628
Cancer Res. 2015 Dec 1;75(23):5014-22
pubmed: 26354021
Onco Targets Ther. 2017 Oct 27;10:5219-5228
pubmed: 29138574